An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease

Trial Profile

An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Adipose-derived autologous stem cell therapy Bioheart (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Therapeutic Use
  • Sponsors U.S. Stem Cell
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to completed.
    • 28 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
    • 04 Apr 2014 New source identified and integrated (ClinicalTrials.gov record; NCT02097862)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top